Scarica l'app Stockscreener
8.405
0.18%
0.025
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PRTA Giù?
Forum
Previsione
Prothena Corporation Plc Borsa (PRTA) Ultime notizie
Prothena Corporation plc stock outlook for YEARPortfolio Profit Report & High Win Rate Trade Alerts - Newser
Strategies to average down on Prothena Corporation plcJuly 2025 Update & Short-Term High Return Ideas - Newser
Is Prothena Corporation plc still worth holding after the dipWeekly Trend Report & Intraday High Probability Setup Alerts - Newser
How institutional ownership impacts Prothena Corporation plc stockWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Can swing trading help recover from Prothena Corporation plc lossesWeekly Stock Recap & Consistent Growth Equity Picks - Newser
Tick level data insight on Prothena Corporation plc volatilityBuy Signal & Free Weekly Chart Analysis and Trade Guides - Newser
Using data models to predict Prothena Corporation plc stock movement2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Earnings visualization tools for Prothena Corporation plcQuarterly Market Review & Real-Time Stock Price Movement Reports - Newser
Is Prothena Corporation plc trending in predictive chart modelsMarket Risk Analysis & Short-Term High Return Ideas - Newser
Relative strength of Prothena Corporation plc in sector analysisJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Ranking Prothena Corporation plc among high performing stocks via tools2025 Technical Overview & Stock Portfolio Risk Management - Newser
Will a bounce in Prothena Corporation plc offer an exitPortfolio Update Summary & Target Return Focused Stock Picks - Newser
Key resistance and support levels for Prothena Corporation plcPrice Action & Expert Curated Trade Ideas - Newser
Will Prothena Corporation plc see short term momentum2025 Trading Recap & Growth Focused Entry Reports - Newser
Recovery Signals Appearing in Prothena Corporation plc Charts2025 Macro Impact & High Conviction Buy Zone Picks - beatles.ru
Is Prothena Corporation plc Forming a Consolidation Base2025 Historical Comparison & Accurate Buy Signal Alerts - beatles.ru
Prothena Corporation plc Stocks Attracting Dip Buyers2025 Support & Resistance & Accurate Intraday Trade Tips - newsyoung.net
Published on: 2025-08-14 23:29:29 - sundaytimes.kr
Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes By Investing.com - Investing.com Canada
Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes - Investing.com
Can trapped investors hope for a rebound in Prothena Corporation plcFree Investment Strategy With Low Risk - Newser
What MACD signals say about Prothena Corporation plcForecast Model for Intraday Buy Signals - Newser
How to escape a deep drawdown in Prothena Corporation plcFree Low Risk High Return Opportunities - Newser
How to build a dashboard for Prothena Corporation plc stockSummary of Reliable Long-Term Trade Models - Newser
Building trade automation scripts for Prothena Corporation plcBreakout Stock Opportunities with Low Drawdown - Newser
Volume spikes in Prothena Corporation plc stock – what they meanFree Safe Entry Stock Watch Suggestions - Newser
How Prothena Corporation plc stock performs during market volatilityLow Exposure Strategy with Sector Analysis - Newser
Trend Reversal Possible in Prothena Corporation plc Charts IndicateSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Royal Bank Of Canada Cuts Prothena (NASDAQ:PRTA) Price Target to $10.00 - Defense World
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - BioSpace
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful - Investing.com India
Prothena (PRTA) Surges on Novo Nordisk's Phase 3 Plans for ATTR Amyloidosis Drug - GuruFocus
Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk - TipRanks
Prothena Announces that Novo Nordisk Will Advance Coramitug (For - GuruFocus
Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential - Stock Titan
Applying sector rotation models to Prothena Corporation plcFree Swing Trading Entry Point Signals - Newser
Prothena announces that Novo Nordisk will advance Coramitug into phase 3 development - MarketScreener
Prothena stock price target lowered to $10 at RBC on program discontinuation By Investing.com - Investing.com South Africa
Prothena stock price target lowered to $10 at RBC on program discontinuation - Investing.com Nigeria
PRTA: RBC Capital Maintains Rating, Lowers Price Target | PRTA S - GuruFocus
9 Analysts Assess Prothena Corp: What You Need To Know - 富途牛牛
Prothena’s Losses Grow As Revenue Drops And Programs Wind Down - Finimize
RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk - MarketScreener
Prothena Corp (PRTA) Maintains 'Buy' Rating with $18 Target by C - GuruFocus
JMP reiterates Market Outperform rating on Prothena stock ahead of key data - Investing.com Nigeria
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - BioSpace
Prothena Reports Q2 2025 Financial Results and Pipeline Progress - TipRanks
0.68%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):